Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data
Abstract
Abstract Recent analyses have suggested a possible negative impact of prior autologous stem cell transplantation on outcomes with idecabtagene vicleucel (ide-cel) chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma. Our registry-based analysis of >800 ide-cel recipients did not identify any such association.
Article Details
Authors (7)
Rahul Banerjee
Christy Khouderchah
1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Othman S. Akhtar
4Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
Emily C. Liang
1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Jordan Gauthier
Madhav V. Dhodapkar
1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Andrew J. Portuguese
Fred Hutchinson Cancer Center, Seattle, Washington, United States